Terms: = Prostate cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1
49 results:
1. mkk4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of Covalent mkk4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract] [Full Text] [Related]
3. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.
Kaur HB; Salles DC; Paulk A; Epstein JI; Eshleman JR; Lotan TL
Histopathology; 2021 Jan; 78(2):327-333. PubMed ID: 32740981
[TBL] [Abstract] [Full Text] [Related]
4. Modeling mek4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Mishra RK; Deibler KK; Clutter MR; Vagadia PP; O'Connor M; Schiltz GE; Bergan R; Scheidt KA
J Chem Inf Model; 2019 Oct; 59(10):4460-4466. PubMed ID: 31566378
[TBL] [Abstract] [Full Text] [Related]
5. Genistein treatment duration effects biomarkers of cell motility in human prostate.
Zhang H; Gordon R; Li W; Yang X; Pattanayak A; Fowler G; Zhang L; Catalona WJ; Ding Y; Xu L; Huang X; Jovanovic B; Kelly DL; Jiang H; Bergan R
PLoS One; 2019; 14(3):e0214078. PubMed ID: 30917169
[TBL] [Abstract] [Full Text] [Related]
6. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective mek4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract] [Full Text] [Related]
7. PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.
Lv C; Fu S; Dong Q; Yu Z; Zhang G; Kong C; Fu C; Zeng Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):24. PubMed ID: 30658679
[TBL] [Abstract] [Full Text] [Related]
8. Gq-Induced Apoptosis is Mediated by AKT Inhibition That Leads to PKC-Induced JNK Activation.
Nadel G; Yao Z; Ben-Ami I; Naor Z; Seger R
Cell Physiol Biochem; 2018; 50(1):121-135. PubMed ID: 30278445
[TBL] [Abstract] [Full Text] [Related]
9. MAP3K1 and map2k4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
Xue Z; Vis DJ; Bruna A; Sustic T; van Wageningen S; Batra AS; Rueda OM; Bosdriesz E; Caldas C; Wessels LFA; Bernards R
Cell Res; 2018 Jul; 28(7):719-729. PubMed ID: 29795445
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNA‑136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen‑activated protein kinase kinase 4.
Zhu Y; Shao S; Pan H; Cheng Z; Rui X
Mol Med Rep; 2018 Mar; 17(3):4803-4810. PubMed ID: 29328468
[TBL] [Abstract] [Full Text] [Related]
11. Androgen-induced miR-27A acted as a tumor suppressor by targeting map2k4 and mediated prostate cancer progression.
Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract] [Full Text] [Related]
13. Mitogen-activated protein kinase kinase 4 (map2k4) promotes human prostate cancer metastasis.
Pavese JM; Ogden IM; Voll EA; Huang X; Xu L; Jovanovic B; Bergan RC
PLoS One; 2014; 9(7):e102289. PubMed ID: 25019290
[TBL] [Abstract] [Full Text] [Related]
14. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.
Ge YZ; Xu LW; Jia RP; Xu Z; Feng YM; Wu R; Yu P; Zhao Y; Gui ZL; Tan SJ; Song Q
Tumour Biol; 2014 Apr; 35(4):3881-90. PubMed ID: 24353088
[TBL] [Abstract] [Full Text] [Related]
15. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.
Krishna SN; Luan CH; Mishra RK; Xu L; Scheidt KA; Anderson WF; Bergan RC
PLoS One; 2013; 8(12):e81504. PubMed ID: 24339940
[TBL] [Abstract] [Full Text] [Related]
16. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents.
Khamis ZI; Iczkowski KA; Sang QX
Med Res Rev; 2012 Sep; 32(5):1026-77. PubMed ID: 22886631
[TBL] [Abstract] [Full Text] [Related]
17. Role of the functional mkk4 promoter variant (-1304T>G) in a decreased risk of prostate cancer: case-control study and meta-analysis.
Shao N; Wang Y; Lu K; Jiang WY; Li Q; Wang N; Feng NH; Hua LX
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1531-9. PubMed ID: 22526163
[TBL] [Abstract] [Full Text] [Related]
18. Gq protein-induced apoptosis is mediated by AKT kinase inhibition that leads to protein kinase C-induced c-Jun N-terminal kinase activation.
Ben-Ami I; Yao Z; Naor Z; Seger R
J Biol Chem; 2011 Sep; 286(35):31022-31031a. PubMed ID: 21757743
[TBL] [Abstract] [Full Text] [Related]
19. Diverse somatic mutation patterns and pathway alterations in human cancers.
Kan Z; Jaiswal BS; Stinson J; Janakiraman V; Bhatt D; Stern HM; Yue P; Haverty PM; Bourgon R; Zheng J; Moorhead M; Chaudhuri S; Tomsho LP; Peters BA; Pujara K; Cordes S; Davis DP; Carlton VE; Yuan W; Li L; Wang W; Eigenbrot C; Kaminker JS; Eberhard DA; Waring P; Schuster SC; Modrusan Z; Zhang Z; Stokoe D; de Sauvage FJ; Faham M; Seshagiri S
Nature; 2010 Aug; 466(7308):869-73. PubMed ID: 20668451
[TBL] [Abstract] [Full Text] [Related]
20. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract] [Full Text] [Related]
[Next]
